Aesculap Implant Systems, LLC
$670.4K 222 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Vascular Graft Solutions Inc
Vascular Graft Solutions Inc reported $668,070.35 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 14 transactions.
- $668.1K Above-median payer
- All-tracks total
- 14 Below-median volume
- Transactions
- 2 Below-median reach
- Recipients
- −$24.1K
- General Payments vs PY2023
Vascular Graft Solutions Inc reported $668,070.35 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #703 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $230.03, averaging $334.0K per recipient.
How Vascular Graft Solutions Inc's $668.1K all-tracks total breaks down
Vascular Graft Solutions Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
12/100
Total payments
F
16/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer vascular-graft-solutions-inc Vascular Graft Solutions Inc
$668.1K · #703/1,925 · 0.0% industry · PY2024
- TOT $668.1K
- RANK #703
- SHARE 0.0%
- TXN 14
- RCP 2
- CAT 1
- GEN $230.03
- ΔGEN −$24.1K
- TOP1 61.4%
- PY 2024
Volume peers
Nearest volume peer: Aesculap Implant Systems, LLC ($670.4K)
Vascular Graft Solutions Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Vascular Graft Solutions Inc's CMS-reported General Payments decreased by $24.1K (−99.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VASCULAR GRAFT SOLUTIONS INCPY2023: VASCULAR GRAFT SOLUTIONS INCPY2024: Vascular Graft Solutions Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $24,307.16
- PY2024
- $230.03
What the Data Shows for Vascular Graft Solutions Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Vascular Graft Solutions Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $230.03, accounting for 100.0% of this company's General Payments and 2 transactions.
General Payment Breakdown by Type
Vascular Graft Solutions Inc made 1 types of general payments. "Food and Beverage" is the largest category at $230.03, 100.0% of General Payments.
How Vascular Graft Solutions Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $230.03 | 2 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $230.03 (100.0%) of $230.03 in this company's General Payments records across 2 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Vascular Graft Solutions Inc
The five named recipients with the highest reported General Payments from this company
- 1
Nirav Patel
$141.13 across 1 reported transactions
- 2
John Perry
$88.90 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Vascular Graft Solutions Inc ranks #703 of 1,925 by total payments (top 37% by spend) but is notably more concentrated than that alone would suggest -- #321 of 1,838 by HHI (top 17% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Shimadzu Precision Instruments, Inc. : $67.9K total payments, HHI 5279
- AppliedVR Inc : $189.1K total payments, HHI 5275
- Partner Therapeutics, Inc. : $378.4K total payments, HHI 5272
- Gyrus ACMI, Inc. : $304.0K total payments, HHI 5269
- Boehringer Ingelheim Espana S.A. : $1.6K total payments, HHI 5266
- BioPoly LLC : $35.8K total payments, HHI 5258
- Vascular Graft Solutions Inc (this company) : $230.03 total payments, HHI 5258
- Nipro Medical Corporation : $8.2K total payments, HHI 5256
- Celgene Corporation : $10.7M total payments, HHI 5254
- Suture Ease, Inc. : $12.9K total payments, HHI 5248
- Dr.Reddy's Laboratories,Inc. : $406.3K total payments, HHI 5228
- Vifor Fresenius Medical Care Renal Pharma Ltd. : $5.0K total payments, HHI 5225
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Vascular Graft Solutions Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Vascular Graft Solutions Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Vascular Graft Solutions Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Teleflex Incorporated
$670.6K 117 recipients
Compare payment profiles
Verathon Inc.
$672.8K 134 recipients
Compare payment profiles
Extremity Medical
$672.9K 438 recipients
Compare payment profiles
Synapse Surgical LLC
$674.2K 0 recipients
Compare payment profiles
Xtant Medical Inc
$659.3K 454 recipients
Compare payment profiles
Put this to use
Vascular Graft Solutions Inc ranks #703 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Vascular Graft Solutions Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.